Our results suggest that disruption of the Hsp110-STAT3 association exhibits therapeutic effects against PAH progression, and provide a promising lead compound to develop the first-in-class agent targeting Hsp110-STAT3 PPI for PAH treatment. This evidence concerns the gene HSPH1 and pulmonary arterial hypertension.